Ascendis Pharma A/S
ASND
173 hedge funds and large institutions have $9.06B invested in Ascendis Pharma A/S in 2020 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 67 increasing their positions, 53 reducing their positions, and 11 closing their positions.
200% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 11
27% more call options, than puts
Call options by funds: $29.7M | Put options by funds: $23.4M
26% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 53
14% more funds holding
Funds holding: 152 → 173 (+21)
10% more capital invested
Capital invested by funds: $8.25B → $9.06B (+$811M)
1.37% more ownership
Funds ownership: 101.43% → 102.81% (+1.4%)
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$148M |
| 2 |
SCM
Spyglass Capital Management
San Francisco,
California
|
+$25.6M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$25.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.8M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$23.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$65.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$41.3M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$29.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$29.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
176
Laurion Capital Management
New York
| – | -$1M | -6,500 | Closed |
|
|
WC
177
Wexford Capital
West Palm Beach,
Florida
| – | -$772K | -5,000 | Closed |
|
|
PCM
178
Prelude Capital Management
New York
| – | -$515K | -3,340 | Closed |
|
179
Squarepoint
New York
| – | -$489K | -3,166 | Closed |
|
|
VIA
180
Vident Investment Advisory
Alpharetta,
Georgia
| – | -$459K | -2,971 | Closed |
|
|
GCP
181
GSA Capital Partners
London,
United Kingdom
| – | -$413K | -2,676 | Closed |
|
|
VF
182
Virtu Financial
New York
| – | -$276K | -1,787 | Closed |
|
|
CG
183
Cutler Group
San Francisco,
California
| – | -$69.5K | -420 | Closed |
|
|
QT
184
Quantbot Technologies
New York
| – | -$30K | -200 | Closed |
|
ASND Hedge Fund Activity: Q4 2020 in Review
173 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2020, worth a combined $9.06B — up 9.8% from $8.25B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ASND positions and 11 closed out — a net gain of 22 holders — while 67 added to existing stakes and 53 trimmed.
The largest buyer was Lone Pine Capital, opening a new position worth an estimated $148M. The largest seller was OrbiMed, cutting an estimated $65.8M.
- 173 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2020, up from 152 in Q3 2020.
- Funds reported $9.06B of Ascendis Pharma A/S stock for Q4 2020, up 9.8% quarter-over-quarter.
- 33 funds opened new Ascendis Pharma A/S positions in Q4 2020 and 11 closed out, a net change of +22 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2020 was Lone Pine Capital, an estimated $148M added.
- The largest Ascendis Pharma A/S seller in Q4 2020 was OrbiMed, an estimated $65.8M sold.
Based on aggregated 13F filings for Q4 2020.